Valuation: Axonics, Inc.

Market Cap 3.63B 3.14B 2.93B 2.69B 5.09B 345B 5.14B 34.42B 13.51B 173B 13.63B 13.32B 572B P/E 2022
-48.9x
P/E 2023 -502x
Enterprise Value 3.31B 2.87B 2.67B 2.46B 4.64B 315B 4.69B 31.41B 12.33B 157B 12.43B 12.16B 522B EV / Sales 2022
10x
EV / Sales 2023 7.74x
Free-Float
99.8%
Yield 2022 *
-
Yield 2023 -
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 53 01/10/2013
Director of Finance/CFO 41 02/10/2023
Chief Operating Officer 47 01/08/2018
Director TitleAgeSince
Director/Board Member 69 01/02/2018
Director/Board Member 74 08/04/2019
Change 5-day change 1-year change 3-year change Capi.($)
-.--%+3.10% - - 3.63B
+0.32%-4.32%-11.51%+18.79% 129B
-1.20%-8.73%-16.72%-1.60% 12.69B
+0.23%+5.73%+94.11%+129.68% 10.05B
+0.24%+0.80%-42.81%-68.91% 4.69B
+0.51%-2.30%-18.54%+36.89% 2.62B
-6.31%+17.66%-31.65%-78.32% 1.85B
-2.20%-0.26%+14.06%-49.05% 1.78B
-2.15%-0.36%-30.54%-32.63% 1.68B
Average -1.17%+1.37%-5.45%-5.64% 20.53B
Weighted average by Cap. +0.07%-3.56%-6.60%+19.44%

Financials

2022 2023
Net sales 274M 237M 221M 203M 384M 26.03B 388M 2.6B 1.02B 13.02B 1.03B 1.01B 43.13B 366M 317M 296M 272M 514M 34.84B 519M 3.48B 1.36B 17.43B 1.38B 1.35B 57.73B
Net income -59.7M -51.7M -48.2M -44.33M -83.69M -5.68B -84.62M -566M -222M -2.84B -224M -219M -9.41B -6.09M -5.27M -4.92M -4.52M -8.53M -579M -8.63M -57.76M -22.67M -290M -22.87M -22.36M -959M
Net Debt -348M -301M -281M -258M -488M -33.1B -493M -3.3B -1.3B -16.56B -1.31B -1.28B -54.85B -317M -275M -256M -236M -445M -30.18B -450M -3.01B -1.18B -15.1B -1.19B -1.17B -50B
Logo Axonics, Inc.
Axonics, Inc. is a medical technology company, which develops and commercializes products to treat adults with bladder and bowel dysfunction. The Company has designed and developed both rechargeable (R20) and recharge-free (F15) implantable sacral neuromodulation (SNM) systems, which deliver mild electrical pulses to the targeted sacral nerve in order to restore normal communication to and from the brain to reduce the symptoms of overactive bladder (OAB), urinary retention (UR) and fecal incontinence (FI). The recharge-free implantable neurostimulator (INS) is approximately 10cc in volume, utilizes constant current stimulation, an easy-to-use, intuitive recharge-free patient remote control and other related accessories. It engineered its recharge-free sacral neuromodulation (SNM) system to deliver constant-current stimulation. Its SNM system includes an easy-to-use wireless patient remote control that does not require recharging or replacement batteries.
Employees
-
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB